Paul Kaufman, MD

Wisconsin Regional Primate Research Center, Animal Health and Biomedical Sciences - School of Veterinary Medicine, Director-Glaucoma Services

M.D. 1967, New York School of Medicine, NY

Bellevue Hospital, New York, NY

Washington University School of Medicine and Barnes Hospital, St. Louis, MO

Ocular Pharmacology Fellowship, Seeing Eye and National Institutes of Health Research Fellow, Departments of Pharmacology and Physiology, University of Uppsalla, Uppsala, Sweden

My research centers on studies of the physiology, pharmacology, morphology, cell biology, genetic manipulation, neural control, biomechanics and aging of the aqueous humor formation and drainage and accommodative mechanisms in the non-human primate, seeking to understand the pathophysiology and develop new therapies for the human diseases of glaucoma and presbyopia.

Glaucoma is the second most common cause of irreversible visual loss in adult Americans, the most common among African Americans, and the most common world-wide, while presbyopia is the most common of all ocular afflictions.

Comparisons of actin filament disruptors and Rho kinase inhibitors as potential antiglaucoma medications.
June 28, 2012

Advances in glaucoma treatment and management: outflow drugs.
May 9, 2012

Imaging and measurement in the eye: now and ahead.
May 5, 2012

Remembering joanne angle, 1941-2012.
April 26, 2012

Structure/Function Studies and the Effects of Memantine in Monkeys with Experimental Glaucoma.
March 20, 2012

1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates.
December 27, 2011